Compare · DCTH vs MDLN
DCTH vs MDLN
Side-by-side comparison of Delcath Systems Inc. (DCTH) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCTH and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 117.6x DCTH ($377.7M).
- Over the past year, DCTH is down 31.5% and MDLN is down 17.1% - MDLN leads by 14.4 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 2 for DCTH).
- MDLN has more recent analyst coverage (25 ratings vs 4 for DCTH).
- Company
- Delcath Systems Inc.
- Medline Inc.
- Price
- $10.93+2.44%
- $33.80+0.58%
- Market cap
- $377.7M
- $44.40B
- 1M return
- -2.76%
- -19.55%
- 1Y return
- -31.52%
- -17.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 2
- 20
- Recent ratings
- 4
- 25
Delcath Systems Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Latest DCTH
- FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC
- Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Sylvester John Richard
- SEC Form 4 filed by Director Martell Bridget A
- SEC Form 4 filed by Director Aharon Gil
- SEC Form 4 filed by Director Salamon Steven A J
- SEC Form 4 filed by Director Czerepak Elizabeth
- SEC Form 8-K filed by Delcath Systems Inc.
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)